Target intelligence / Profile preview

Bridging integrator 1 (BIN1)

Target
BIN1
Molecular classification
Adapter protein, BAR (Bin/Amphiphysin/Rvs) domain-containing protein, Other
01

Overview

Bridging integrator 1 (BIN1) is a nucleocytoplasmic adaptor protein encoded by the BIN1 gene. It belongs to the BAR adapter family of proteins that regulate membrane curvature and remodeling. Multiple isoforms exist due to alternative splicing; these isoforms have tissue-specific functions in the central nervous system, muscle cells, heart tissue, immune cells, and more. In neurons it participates in synaptic vesicle endocytosis; in muscle it is essential for T-tubule formation critical for excitation-contraction coupling. BIN1 acts as a tumor suppressor by interacting with c-MYC to inhibit its transcriptional activity. Loss or mutation of BIN1 has been implicated as a genetic risk factor for late-onset Alzheimer’s disease—likely through disruption of tau homeostasis at synapses—and causes various inherited skeletal myopathies characterized by progressive muscle weakness. In cancer biology it is frequently silenced or misspliced during malignant progression. The structure includes an N-terminal BAR domain responsible for membrane binding/tubulation and a C-terminal SH3 domain mediating interactions with other proteins such as phospholipase D isoforms.

Other names
Myc box-dependent-interacting protein 1Amphiphysin-2BIN1
02

Biological functions

Membrane binding and tubulationCell polarity regulationVesicle traffickingTranscriptional regulation (including c-MYC interaction)Cognition and memory modulationMuscle function (T-tubule formation)Immunomodulation and barrier functionCardiac muscle development and functionTumor suppression and apoptosis induction
03

Disease associations

Neurodegenerative disease (notably Alzheimer’s disease)Skeletal myopathies (e.g., centronuclear myopathy, myotonic dystrophy)Cancer/tumor suppressionCardiovascular disease (cardiomyopathy, heart failure)
04

Safety considerations

No direct safety concerns reported for therapeutic targeting; however, loss-of-function mutations or reduced expression are linked to muscle weakness, cardiac dysfunction, neurodegeneration, and cancer progression
05

Biomarkers

BIN1 polymorphisms are associated with increased risk for late-onset Alzheimer’s disease; loss or altered splicing of BIN1 is a biomarker in certain skeletal myopathies and cancers

Beyond the preview

Go deeper on Bridging integrator 1 (BIN1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bridging integrator 1 (BIN1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call